Amal O. Alotaibi, Ghada A. Alsowailmi, Sara I. Alshahwan, Afnan A. Alsahli and Yaser M. Almalik
Fingolimod is the rst oral agent approved for the management of relapsing reming mulple sclerosis (RRMS). It was shown to reduce the progression and relapse rate of neurological disability by 30% and 54%, respecvely. Reported adverse eects of the drug include bradycardia, elevated liver enzymes, mild hypertension, and macular edema. No associaon between ngolimod and renal infarcon as an adverse eect has been presented to date. We report a case of a 45-year-old male paent with RRMS, who presented with renal infarcon and was treated with ngolimod
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu